Skip to content
Menu

IDEAYA Biosciences, Inc. IDYA

Full chart Compare
Set alert

Price alert · IDYA

All alert types
26.17 USD -0.32 (-1.21%)

Regular-session close

26.17 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

25.75 Day range 27.44
25.75 52-week range 42.68
YTD
-24.30%
1 year
-21.01%

5D -3.95 (-12.60%)

283032WedThuFriMonTue27.40
Market cap
2.53B
Revenue (ttm)
36.54M
EPS (ttm)
-4.50
Shares out
96.69M
Forward P/E
-6.24
YTD return
-24.30%
1-year return
-21.01%
50-day average
34.81
200-day average
33.77
Enterprise value
1.75B
Volume
1.42M
Avg volume
932.95K
Open
26.57
Previous close
26.49
Day's range
25.75 – 27.44
52-week range
25.75 – 42.68
Beta
0.08
Analysts
Strong Buy
Price target
50.69 (+93.7%)
Earnings date
Feb 16, 2027

Key statistics

Price / sales
69.26
Price / book
2.32
Revenue growth
-95.10%
Free cash flow
-214.22M
Total cash
838.54M
Total debt
29.70M
Return on equity
-38.46%
Short % of float
9.89%

Fundamental scorecard

5 of 25 checks passed on IDYA’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IDYA Revenue — quarterly 10.24M
IDYA Net income — quarterly -125.75M
IDYA EPS — quarterly -1.22

Earnings

IDYA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 30, 2026-1.18———
Nov 3, 2026Sep 30, 2026-1.18-1.22-0.04-3.39%
Aug 4, 2026Jun 30, 2026-1.06-1.22-0.16-15.09%
May 5, 2026Mar 31, 2026-1.07-1.11-0.04-3.74%
Feb 17, 2026Dec 31, 2025-0.95172-0.94+0.01+1.23%
Nov 4, 2025Sep 30, 2025-0.945971.33+2.28+240.60%

Upgrades / downgrades

IDYA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026MizuhomainOutperformOutperform
Nov 5, 2026CitigroupmainBuyBuy
Nov 4, 2026RBC CapitalmainOutperformOutperform
Nov 4, 2026Truist SecuritiesreitBuyBuy
Nov 4, 2026GuggenheimmainBuyBuy
Nov 4, 2026WedbushmainOutperformOutperform

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on IDYA — it syncs with the Stock Master app.

Insider holders

IDYA insider holders
InsiderRelationLatest transactionDateShares held
HATA YUJIRO S.Chief Executive OfficerSaleOct 5, 2026690,695
RUIZ BRISENO ANDRESOfficerSaleJul 6, 202626,466
SNYDER DOUGLAS BGeneral CounselStock Award(Grant)Nov 27, 20252,080
STEIN JEFFREYDirectorPurchaseMar 1, 202661,007

Institution ownership

IDYA institution ownership
Holder% heldSharesValueReported
FMR, LLC14.97%14,472,529378.75MSep 29, 2026
Blackrock Inc.9.87%9,548,534249.89MSep 29, 2026
Janus Henderson Group Ltd.8.92%8,622,814225.66MSep 29, 2026
Capital Research Global Investors5.52%5,340,938139.77MSep 29, 2026
Baker Bros. Advisors, LP5.18%5,010,030131.11MSep 29, 2026
Vanguard Capital Management LLC4.46%4,311,706112.84MSep 29, 2026

Fund ownership

IDYA fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc5.38%5,202,950136.16MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund4.95%4,790,196125.36MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.07%2,964,95077.59MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.42%2,337,66061.18MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.64%1,586,60241.52MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund1.42%1,369,22435.83MSep 29, 2026